MedWatch

Lundbeck loses top-line terrain but surpasses expectations

Sales of the drug Northera, which is no longer protected by patents, plummeted in Lundbeck's first quarter, while most other key products surpassed analysts' forecasts. This means the firm brought in more revenue than the market expected.

Photo: Jens Dresling

Lundbeck maintains its guidance for 2021 since the company's first quarter ended significantly better than what the market had expected.

In total, Lundbeck landed at a DKK 4.274bn (USD 698.8m) revenue, down from the DKK 4.564bn the company secured in the first three months of 2020. It should, however, be taken into consideration that at this point, the firm was positively affected by stockpiling owing to the Covid-19 pandemic. Nevertheless, this is better than the DKK 4.208bn which analysts estimated.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs